[go: up one dir, main page]

US20030087813A1 - Cyclosporin analogs for the treatment of lung diseases - Google Patents

Cyclosporin analogs for the treatment of lung diseases Download PDF

Info

Publication number
US20030087813A1
US20030087813A1 US09/975,923 US97592301A US2003087813A1 US 20030087813 A1 US20030087813 A1 US 20030087813A1 US 97592301 A US97592301 A US 97592301A US 2003087813 A1 US2003087813 A1 US 2003087813A1
Authority
US
United States
Prior art keywords
formula
ala
αabu
compound
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/975,923
Other languages
English (en)
Inventor
Yat Or
Tsvetelina Lazarova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enanta Pharmaceuticals Inc
Original Assignee
Enanta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharmaceuticals Inc filed Critical Enanta Pharmaceuticals Inc
Priority to US09/975,923 priority Critical patent/US20030087813A1/en
Assigned to ENANTA PHARMACEUTICALS, INC. reassignment ENANTA PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OR, YAT SUN, LAZAROVA, TSVETELINA IVANOVA
Priority to AU2002362774A priority patent/AU2002362774A1/en
Priority to PCT/US2002/032646 priority patent/WO2003030834A2/fr
Priority to US10/345,855 priority patent/US20030109425A1/en
Priority to US10/349,877 priority patent/US6979671B2/en
Publication of US20030087813A1 publication Critical patent/US20030087813A1/en
Assigned to SILICON VALLEY BANK DBA SILICON VALLEY EAST reassignment SILICON VALLEY BANK DBA SILICON VALLEY EAST SECURITY AGREEMENT Assignors: ENANTA PHARMACEUTICALS, INC.
Assigned to ENANTA PHARMACEUTICALS, INC. reassignment ENANTA PHARMACEUTICALS, INC. SECURITY AGREEMENT Assignors: SILICON VALLEY BANK DBA SILICON VALLEY EAST
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel cyclosporin analogs and methods for the treatment of asthma and other diseases characterized by airflow obstruction in a subject.
  • the present invention further relates to pharmaceutical compositions comprising the compounds of the present invention and processes for their production.
  • Respiratory diseases such as asthma and other diseases characterized by airflow obstruction
  • airflow obstruction a global problem. Millions of people worldwide, both children and adults, suffer from these medical conditions. These diseases reduce quality of life by impairing the ability of sufferers to perform everyday tasks, and in some cases, cause death.
  • One of the major respiratory diseases is asthma.
  • Asthma is a disease of unknown etiology in which the bronchi are inflamed and as a consequence obstructed. This narrowing results from a combination of bronchial smooth muscle contraction, mucosal oedema, inflammatory cell infiltrate and partial or total occlusion of the lumen with mucus, cells and cell debris. Bronchial obstruction is either partially or totally reversible, and this important feature distinguishes asthma from chronic bronchitis.
  • Asthma is an extremely common disease with a worldwide prevalence of 5% to 8%. In the developed world it is the most common chronic illness and, for reasons that are unclear, the disease is on the increase. It is now accepted that asthma is a chronic inflammatory disorder of the airways in which many cells play a role, in particular, mast cells, eosinophils and T-lymphocytes. In susceptible individuals this inflammation causes symptoms which are usually associated with widespread but variable airflow obstruction. This type of airflow obstruction is often reversible either spontaneously or with treatment and causes associated increase in airway responsiveness to a variety of stimuli.
  • the illness has a wide clinical spectrum ranging from mild episodic bronchospasm (easily controlled by the occasional use of a bronchodilator) to a very severe intractable asthma sometimes resistant to treatment with high doses of oral corticosteroids.
  • Steroid resistance occurs in less than 5% of people with asthma. This translates to thousands of people.
  • These patients with severe chronic disease may be dependent on corticosteroids and their disease is often so severe that full reversibility can be difficult or impossible to demonstrate.
  • COPD chronic obstructive airways disease
  • chronic obstruction lung disease and ‘smoker's chest’ have all been used to describe what is now known as COPD.
  • COPD is characterized by progressive irreversible airway obstruction. It can lead to death from respiratory or cardio-respiratory failure.
  • COPD consists of two subsets: chronic bronchitis and emphysema. In practice, it is very difficult to define the contribution of each of these two conditions to the obstruction of the airway and this has led to the displacement of these labels by the non-specific term COPD.
  • the pathology of COPD is not fully elucidated, but features include hypertrophy of mucus-secreting glands, inflammation (including infiltration with lymphocytes) and goblet cell hyperplasia.
  • COPD chronic obstructive pulmonary disease
  • Cystic fibrosis is an inherited condition. Excess viscid mucus is produced. This leads to recurrent chest infections and progressive bronchiectasis. Approximately 50% of cystic fibrosis sufferers have bronchial hyperresponsiveness and there is an increased incidence of atopy. There is widespread airway narrowing and wheeze. Most cystic fibrosis sufferers take bronchodilators, some take inhaled corticosteroids. And at least one study had reported benefit with oral corticosteroids.
  • corticosteroids such as beclomethasone, triamcinolone
  • beta adrenergics such as epinephrine, albuterol, bitolterol
  • NSAIDS leukotriene antagonists
  • Xanthines methyl xanthines such as theophylline, oxtriphylline
  • anticholinergics such as atropine, ipratropium bromide
  • Corticosteroids are the mainstay of treatment of chronic asthma and they revolutionized the treatment of this disease when they were first introduced in the 1950's. Oral corticosteroids have today been largely replaced by inhaled corticosteroids, although severe asthmatics still require medication by mouth. Inhaled cortisteroids are relatively safe and extremely effective in most patients, and improved the quality of life for millions of asthmatic sufferers. For those with severe asthma, however, oral therapy with corticosteroids is required. When taken for more than a few days oral corticosteroids have a number of serious side effects. These include growth retardation in children, severe osteoporosis (especially in old age), decreased responsiveness of the pituitary adrenal axis to stress, fluid retention, diabetes and precipitation of psychosis.
  • corticosteroids are effective for asthma, they are not ideal drugs. Over the years doctors have occasionally used immunosuppressive agents as adjuncts to corticosteroids in patients with extremely severe disease. Examples of immunosuppressive drugs are azathioprine, methotrexate, mycophenolic acid and prodrug, leflunomide, Cyclosporin A, ascomycin, FK-506 and rapamycin.
  • the cyclosporins comprise a class of structurally distinctive, cyclic, poly-N-methylated undecapeptides, commonly possessing pharmacological activity, in particular immunosuppressive, anti-inflammatory or anti-parasitic activity.
  • the first of the cyclosporins to be isolated was the naturally occurring fungal metabolite cyclosporin, Cyclosporin A represented as follows:
  • Cyclosporin A (hereinafter “CsA”) is active against CD4+ lymphocytes and might, therefore, be useful for asthma.
  • CsA Cyclosporin A
  • CsA binds to the ubiquitous protein cyclophilin, in the cytosol, and the complex in turn binds to calcineurin, which is a calcium and calmodulin dependent serine threonine phosphatase.
  • Calcineurin is necessary for the cytoplasmic portion of the transcription factor NF-AT, a nuclear factor of activated T-cells, to translocate to the nucleus and bind to its nuclear portion to become an active transcription factor.
  • NF-AT forms a complex with AP-1 and regulates the transcription of the IL-2 gene, together with other genes, for example, IL-5.
  • CsA prevents the cytoplasmic portion of NF-AT from translocating, resulting in reduced transcription of IL-2.
  • CsA has a specific inhibitory effect in CD4+ cells through this transcription mechanism, but may also have inhibitory effects on other cells, including mast cells and eosinophils, through mechanisms that have not yet been defined.
  • CsA 5 mg/kg/day allowed a significant reduction in the use of corticosteroids by 60%.
  • Side effects with systemic CsA were increase in diastolic blood pressure and decrease in renal function.
  • Other side effects include hepatic dysfunction, hypertrichosis, tremor, gingival hyperplasis and paraesthesia.
  • the systemic toxicity of CsA limits its use for the treatment of asthma, COPD and other related lung diseases. Therefore, it is desirable to synthesize analogs of CsA which retain CsA's potential utility as a primary or adjunct therapy for respiratory diseases, while reducing or eliminating CsA's systemic toxicity.
  • the present invention relates to novel cyclosporin analogs and methods of treatment for the treatment of asthma and other diseases characterized by airflow obstruction in a subject.
  • the present invention further relates to pharmaceutical compositions comprising the compounds of the present invention and processes for their production.
  • the present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof:
  • X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-;
  • Y is selected from the groups: —C(O)—O—R1; —C(O)—S—R1; —C(O)—OCH 2 —OC(O)R2; —C(S)—O—R1; and —C(S)—S—R1; where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio or halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio and where R2 is C1-C6 alkyl optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio heterocyclics or aryl;
  • B is - ⁇ Abu-,
  • the present invention relates to the use of the cyclosporin analogs of the present invention or a pro-drug or a pharmaceutically acceptable salt thereof in pharmaceutical compositions for the treatment of asthma and other diseases characterized by airflow obstruction in a subject.
  • the present invention relates to processes for the production of novel cyclosporin analogs of the present invention.
  • the present invention relates to the processes for the production of cyclosporin analogs of formula I, with the structure of residue A as illustrated above.
  • the present invention also contemplates method(s) of treatment of asthma and other diseases characterized by airflow obstruction in a subject by administering to the subject therapeutically effective amounts of the cyclosporin analogs of the present invention with or without the concurrent use of other drugs or pharmaceutically acceptable carriers or excipients.
  • the present invention relates to novel cyclosporin analogs and methods of treatment for the treatment of asthma and other diseases characterized by airflow obstruction in a subject.
  • the present invention further relates to pharmaceutical compositions comprising the compounds of the present invention and processes for their production.
  • the patents and publications identified in this specification indicate the knowledge in this field and are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure will prevail.
  • the present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof:
  • X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-;
  • Y is selected from the groups: —C(O)—O—R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy or halogen substituted C1-C6 alkylthio; —C(O)—S—R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy or halogen substituted C1-C6 alkylthio; —C(O)—OCH 2 —OC(O)R2 where R2 is C(O
  • a cyclosporin analog of the present invention is represented by formula I or a pro-drug or pharmaceutically acceptable salt thereof, where residue B is - ⁇ Abu- and residue U is -(D)Ala-.
  • the cyclosporin analog of the present invention is represented by formula I or a pro-drug or pharmaceutically acceptable salt thereof, where X is absent in residue A, residue B is - ⁇ Abu- and residue U is -(D)Ala-.
  • Representative compounds of the invention include, but are not limited to, the following compounds as illustrated below:
  • Cyclosporin analogs of the invention are accordingly useful for the treatment of diseases or conditions responsive to or requiring topical anti-inflammatory, immunosuppressive or related therapy, for example, topical administration for the treatment of such diseases or conditions of the eye, nasal passages, buccal cavity, skin, colon or, especially, airways or lung.
  • topical anti-inflammatory, immunosuppressive or related therapy permit topical anti-inflammatory, immunosuppressive or related therapy with the concomitant avoidance or reduction of undesirable systemic side effects, for example general systemic immunosuppression.
  • Cyclosporin analogs of the invention useful for the treatment of diseases and conditions of the airways or lung, in particular, inflammatory or obstructive airway diseases. They are especially useful for the treatment of diseases or conditions of the airways or lungs associated with or characterized by inflammatory cell infiltration or other inflammatory events accompanied by inflammatory cell accumulation, for e.g., eosinophil and/or neutrophil. Most preferably, they are useful for the treatment of asthma.
  • Cyclosporin analogs of the invention are useful in the treatment of asthma of whatever type of genesis including both intrinsic and, especially, extrinsic asthma. They are useful for the treatment of atopic and non-atopic asthma, including allergic asthma, bronchitic asthma, exercise induced asthma, occupational asthma, asthma induced following bacterial infection and other non-allergic asthmas. Treatment of asthma is also to be understood as embracing treatment of “whez-infant syndrome,” that is treatment of subjects, for example, of less than 4 to 5 years of age, exhibiting wheezing symptoms, in particular at night, and diagnosed or diagnosable as “whez infants,” an established patient category of major medical concern and now more correctly indentified as incipient or early-phase asthmatics. Cyclosporin analogs of the invention are in particular useful for the treatment of asthma in subjects whose asthmatic status is either steroid dependent or steroid resistant.
  • Cyclosporin analogs of the invention are also useful for the treatment of bronchitis or for the treatment of chronic or acute airways obstruction associated therewith. Cyclosporin analogs of the invention may be used for the treatment of bronchitis of whatever type or genesis, including, for example, acute bronchitis, arachidic bronchitis, catarrhal bronchitis, chronic bronchitis, croupous bronchitis, phthinoid bronchitis and so forth.
  • Cyclosporin analogs of the invention are in addition useful for the treatment of pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, berylliosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and, in particular, byssinosis.
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • pneumoconiosis an inflammatory, commonly occupational
  • Cyclosporin analogs of the invention may also be used for the treatment of eosinophil-related disorders of the airways (e.g. involving morbid eosinophilic infiltration of pulmonary tissues) including hypereosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil-related disorders of the airways consequential or concomitant to Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
  • eosinophil-related disorders of the airways e.g. involving morbid eosinophilic infiltration of pulmonary tissues
  • hypereosinophilia
  • treatment as used herein in relation to the treatment of diseases of the airways and lungs, in particular asthma, is to be understood as embracing both symptomatic and prophylactic modes, that is for immediate treatment, for e.g., of acute inflammation (symptomatic treatment) as well as for advance treatment to prevent, ameliorate or restrict long term symptomatology (prophylactic treatment).
  • treatment as used in the present specification and claims in relation to such diseases is to be interpreted accordingly as including both symptomatic and prophylactic treatment, for e.g., in the case of asthma, symptomatic treatment to ameliorate acute inflammatory events and prophylactic treatment to restrict on-going inflammatory status and to ameliorate future bronchial exacerbation associated therewith.
  • Cyclosporin analogs of the invention may also be used to treat any disease or condition of the airways or lungs requiring immunosuppressive therapy, for e.g., the treatment of autoimmune diseases, or as they affect, the lungs (for example, for the treatment of sarcoidosis, alveolitis or chronic hypersensitivity pneumonitis) or for the maintainance of allogenic lung transplant, for e.g., following lung or heart lung transplantation.
  • immunosuppressive therapy for e.g., the treatment of autoimmune diseases, or as they affect, the lungs (for example, for the treatment of sarcoidosis, alveolitis or chronic hypersensitivity pneumonitis) or for the maintainance of allogenic lung transplant, for e.g., following lung or heart lung transplantation.
  • cyclosporin analogs of the invention will be administered topically within the airways, for e.g., by the pulmonary route or by inhalation.
  • cyclosporin analogs of the invention exhibit reduced systemic toxicity.
  • Cyclosporin analogs of the invention thus provide a means for the treatment of diseases and conditions of the airways or lung, for example, as hereinabove set forth, with the avoidance of unwanted systemic side effect, e.g. consequent to inadvertent swallowing of drug substance during inhalation therapy. It is estimated that during the course of manoeuvres required to effect administration by inhalation, up to 90% or more of total drug substance administered will normally be swallowed rather than inhaled.
  • cyclosporin analogs which are topically active, e.g. effective when inhaled, but systemically inactive
  • the present invention makes cyclosporin therapy available to subjects for whom such therapy might otherwise be excluded, e.g. due to the risk of systemic, in particular immunosuppressive, side effect.
  • Further uses include the treatment and prophylaxis of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses, such as psoriasis, atopical dermatitis, contact dermatitis and further eczematous dermatitises, seborrhoeis dermatitis, Lichen planus, Pemphigus, bullous pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Lupus erythematosus, acne and Alopecia areata; various eye diseases (autoimmune and otherwise) such as keratoconjunctivitis, vernal conjunctivitis, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer
  • the compounds of the present invention may also find utility in the chemosensitization of drug resistant target cells.
  • Cyclosporin A and FK-506 are known to be effective modulators of P-glycoprotein, a substance which binds to and inhibits the action of anticancer drugs; by inhibiting P-glycoprotein, they are capable of increasing the sensitivity of multidrug resistant (MDR) cells to chemotherapeutic agents. It is believed that the compounds of the invention may likewise be effective at overcoming resistance expressed to clinically useful antitumour drugs such as 5-fluorouracil, cisplatin, methotrexate, vincristine, vinblastine and adriamycin, colchicine and vincristine.
  • compositions of the present invention comprise a therapeutically effective amount of a cyclosporin analog of the invention in combination with a pharmaceutically acceptable carrier or excipient.
  • compositions pertaining to the present invention are useful for treating a subject for a reversible obstructive airway disease.
  • the present invention also contemplates method(s) of treatment of asthma and other diseases characterized by airflow obstruction in a subject by administering to the subject therapeutically effective amounts of the cyclosporin analogs of the present invention with or without the concurrent use of other drugs or pharmaceutically acceptable carriers or excipients, as described throughout the present specification.
  • Such treatment of the disease may be done by administering a therapeutically effective amount of a compound of the invention for such time and in such amounts as is necessary to produce the desired result.
  • “therapeutically effective amount” of one of the compounds means a sufficient amount of the compound to treat a particular disease, at a reasonable benefit/risk ratio.
  • the compounds of the present invention may be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug forms.
  • the compound may be administered as pharmaceutical compositions containing the compound of interest in combination with one or more drugs or pharmaceutically acceptable excipients. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
  • Dosages of the cyclosporin analogs of the present invention employed in practicing the method of the present invention will of course vary depending on the site of treatment, the particular condition to be treated, the severity of the condition, the subject to be treated (for e.g., in terms of body weight, age and so forth) as well as the effect desired.
  • cyclosporins of the invention can be suitably administered topically to the airways or lungs, for e.g., but not limited to, inhalation, at dosages from about 20 to about 400 mg/day, preferably from about 50 to about 300 mg/day, most preferably from about 200 to about 300 mg/day.
  • Dosages will appropriately be administered from a metered delivery system in a series of from 1 to 5 puffs at each administration, with administration performed once to four times daily. Dosages at each administration will thus conveniently be from about 5 to 100 mg/day, more preferably from about 12.5 to about 100 mg/day, e.g.
  • a metered delivery device capable of delivering, for e.g., 1 to 25 mg cyclosporin per actuation.
  • a metered delivery device capable of delivering, for e.g., 1 to 25 mg cyclosporin per actuation.
  • more preferable doses may be in the range from about 0.005 to about 3 mg/kg/day.
  • the effective daily dose may be divided into multiple doses for purposes of administration; consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
  • C 1 -C 3 -alkyl or “C 1 -C 6 -alkyl” as used herein refer to saturated, straight- or branched-chain hydrocarbon radicals containing between one and three or one and six carbon atoms, respectively.
  • Examples of C 1 -C 3 alkyl radicals include methyl, ethyl, propyl and isopropyl
  • examples of C 1 -C 6 -alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl and n-hexyl.
  • C 1 -C 6 -alkoxy refers to an C 1 -C 6 -alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom.
  • Examples of C 1 -C 6 -alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy and n-hexoxy.
  • C 1 -C 6 -alkylthio refers to an C 1 -C 6 -alkyl group, as previously defined, attached to the parent molecular moiety through a sulfur atom.
  • Examples of C 1 -C 6 -alkylthio include, but are not limited to, thiomethoxy, thioethoxy, thiopropoxy, thio-isopropoxy, n-thiobutoxy, tert-thiobutoxy, neothiopentoxy and n-thio-hexoxy.
  • aryl refers to a carbocyclic ring system having one or more aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like.
  • Aryl groups can be unsubstituted or substituted with one, two or three substituents independently selected from lower alkyl, substituted loweralkyl, haloalkyl, alkoxy, thioalkoxy, lower alkylenedioxy, lower alkylidenedioxy, amino, alkylamino, dialkylamino, acyamino, cyano, hydroxy, acyl, halo and/or trifluoromethyl, mercapto, nitro, carboxylaldehyde, carboxy, alkoxycarbonyl, carbamoyl, sulfamoyl, lower alkoxycarbonylamino, lower alkanoyl, ureido, amidino and carboxamide.
  • substituted aryl groups include tetrafluorophenyl and pentafluorophenyl.
  • C 3 -C 6 -cycloalkyl- refers to carbocyclic groups of 3 to 6 carbons, respectively; for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • halo and “halogen” as used herein refer to an atom selected from fluorine, chlorine, bromine and iodine.
  • heterocyclics refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
  • subject refers to a mammal or animal.
  • mammal is a human.
  • a subject refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs and the like.
  • pro-drug refers to pharmacologically acceptable derivatives, for example, but not limited to, esters and amides, such that the resulting biotransformation product of the derivative is the active drug.
  • Pro-drugs are known in the art and are described generally in, e.g., Goodman and Gilman's “Biotransformation of Drugs,” in the Pharmacological Basis of Therapeutics, 8 th Ed., McGraw Hill, Int. Ed. 1992, page 13-15, which is hereby incorporated by reference in its entirety.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977), incorporated herein by reference.
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsultate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, per
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sultonate and aryl sulfonate.
  • compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers.
  • pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminun hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lau
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Pharmaceutically acceptable diluents or carriers may be diluents or carriers acceptable for topical application at the intended site of therapy, e.g. diluents or carriers acceptable for topical administration pulmonary, dermally, nasally, ocularly or rectaly.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • Forms in topically administrable form include, e.g. dry powder preparations of the active ingredient (i.e. cyclosporin analog of the invention) in substantially pure form, for example as employed in the art for delivery from a dry powder inhalation device.
  • Means or devices enabling or facilitating topical administration include, in particular, inhalation devices as well as containers and the like from which the active ingredient may be delivered in a form capable of topical application.
  • Preferred embodiments as defined under C will be such as permit topical administration within the airways or lungs, e.g. by inhalation.
  • Preparation of forms suitable for administration by inhalation may be carried out by methods known in the art. It should be noted that several antibiotics have recently developed for topical inhaled usage, particularly in cystic fibrosis, where they have been shown to be effective against pseudomonas infections. Various inhalants are described. For example, in DE 1491707, GB 1,392,945, GB 1,457,351, GB 1,457,352, NL 147939, DE 1491715, GB 1,598,053, EP 5585, EP 41783, EP 45419, EP 360463 and FR 2628638. DE 1491715, in particular, is said to be suitable for inhalation therapy intended for bronchial or lung diseases.
  • cyclosporin analogs of the invention may be employed in any suitable finely dispersed or finely dispersible form, capable of administration into the airways or lungs, for example in finely divided dry particulate form or in dispersion or solution in any appropriate (i.e. pulmonarily administerable) solid or liquid carrier medium.
  • cyclosporin analogs of the invention may, for example, be employed as such, i.e. in micronised form without any additive materials, in dilution with other appropriate finely divided inert solid carrier or diluent (e.g. glucose, lactose, mannitol, sorbitol, ribose, mannose or xylose), in coated particulate form or in any other appropriate form as know in the art for the pulmonary administration of finely divided solids.
  • diluent e.g. glucose, lactose, mannitol, sorbitol, ribose, mannose or xylose
  • Pulmonary administration may be effected using any appropriate system as known in the art for delivering drug substance in dry or liquid form by inhalation, e.g. an atomizer, nebulizer, dry-powder inhaler or like device.
  • a metered delivery device i.e. capable of delivering a pre-determined amount of cyclosporin analog at each actuation, will be employed.
  • Such devices are known in the art.
  • cyclosporin analogs of the invention will suitably be administered in liquid form from a nasal applicator.
  • suitable topical forms for the treatment of diseases or conditions of the skin will include, for example, creams, gles, ointments, pastes, cataplasms, plasters, transdermal patches and the like.
  • Formulations for dermal application will appropriately contain a skin penetration enhancer, e.g. as know in the art, for example azone.
  • Forms suitable for ophthalmic use will include lotions, tinctures, gels, ointment and ophthalmic inserts, again as known in the art.
  • cyclosporin analogs of the invention may be administered in suppository or enema form, in particular in solution, e.g. in vegetable oil or like oily system for use as a retention enema.
  • cyclosporin analogs may be used for the manufacture of a topical preparation for the treatment, with or without the concurrent use of other drugs.
  • cyclosporin analogs of the invention may be employed in any dosage form appropriate for topical administration to the desired site.
  • cyclosporin analogs of the invention may be administered via the pulmonary route, by inhalation from an appropriate dispenser device.
  • Dosage for the topical preparation will in general be one tenth to one hundredth, of the dose required for oral preparation.
  • Abbreviations Sar: Sarcosine MeLeu: N-Methyl-Leucine Val: Valine Ala: Alanine MeVal: N-Methyl Valine Et: Ethyl Ph: Phenyl Fmoc: 9-Fluorenylmethoxycarbonyl- MeBmt: N-Methyl-(4R)-4-[(E)-2-butenyl]-4-methyl-L-threonine ⁇ -Abu: ⁇ -Aminobutyric acid
  • the compounds and processes of the present invention will be better understood, but are not limited to, the following synthetic scheme which illustrates the methods by which the compounds of the present invention (illustrated by formula I) may be prepared.
  • the groups X and Y, and the amino acid residues B and U in formula I are as defined earlier in the specification.
  • the starting material for Scheme I, illustrated by formula I where A′-MeBmt- may be, for example, but not limited to, a fermentation product or a synthetic product made by solution phase chemistry.
  • the starting material is commercially available.
  • the starting material as a fermentation product may be made from highly productive strains, for example, but not limited to, Sesquicillopsis rosariensis G.
  • the starting material may be made by solution phase chemistry either by sequentially assembling amino acids or by linking suitable small peptide fragments, where the units are linked by, for example, but not limited to, amide, ester or hydroxylamine linkages (described in, Müller, Methoden der organischen, Chemie Vol.
  • amide linkages particular preference is given to the azide method, the symmetric and mixed anhydride method, in situ generated or preformed active esters and methods using coupling reagents (e.g., dicyclohexylcarbodiimide, N,N-dimethyl-4-aminopyridine, N-hydroxy-benzotriazole, PyBrop® etc.).
  • coupling reagents e.g., dicyclohexylcarbodiimide, N,N-dimethyl-4-aminopyridine, N-hydroxy-benzotriazole, PyBrop® etc.
  • Classical solution phase chemistry using standard Z- and Boc- methodology may be used.
  • Residue A which is -MeBmt- in the starting material is further modified, as illustrated in the following reaction scheme.
  • the process for the preparation of the compounds of formula I comprises reacting a compound of formula I where A′ ⁇ -MeBmt- (for example, Cyclosporin A) with an olefin having a terminal double bond with catalysts such as Grubb's ruthenium alkylidene, Grubbs dihydroimidazole ruthenium, Shrock-Hoveyda molybdenum catalysts or benzylidene catalysts [see (a) U.S. Pat. 6,111,121; (b) Reviews: Synlett, 1999, 2, 267; (c) Reviews: Ivin, K J; Mol, J. C.
  • a lithium salt such as lithium bromide, lithium chloride, lithium trifluoroacetate, lithium triflate of a lewis acid such as titanium isopropoxide
  • the organic solvent used may be solvents such as, for example, dichloromethane, chloroform, toluene, benzene, tetrahydrofuran, dimethylformamide and the like or mixtures thereof.
  • the reaction may be carried out from room temperature to about 100° C. for 1-7 days to provide a compound of formula I, where residue A′ is converted to residue A′′ having formula (i).
  • the organic solvents used can be solvents such as methanol, ethanol, ethyl acetate or mixtures thereof.
  • Other catalysts useful to assist hydrogenation may be, for example, but not limited to, platinum metal or its oxide [see standard books on catalytic hydrogenation, e.g., Rylander, P. N., Hydrogenation Methods, Academic Press: NY, 1985; Catalytic Hydrogenation in Organic Synthesis, Academic Press: NY, 1985; ⁇ haeck over (C) ⁇ erven ⁇ , L., Catalytic Hydrogenation, Elsevier: NY, 1986 etc.].
  • the reaction may be carried out at room temperature or elevated temperature, for example, but not limited to, 50° C. or 100° C.
  • the cyclosporin analogs of the present invention have potent immunosuppressive and anti-inflammatory activity. In particular, they inhibit antigen-induced inflammatory cell infiltration, for example, into the airways. In vivo this activity is apparent following topical administration, e.g., pulmonary route.
  • calcineurin inhibition is widely used as an in vitro measure of the activity of cyclosporin analogs.
  • IC 50 values were calculated from determinations of enzyme activity at inhibitor concentrations ranging from 0.1 to 0.0015 ⁇ M.
  • NFAT activation follows precisely the activation of calcineurin by increased free calcium levels in the cytoplasm.
  • researchers from diverse fields are interested in the NFAT family of transcription factors, which are potential targets for newer and safer immunosuppressive drugs.
  • the activation of NFAT proteins involves various cellular signal transduction pathways, including calcium mobilization and MAP kinase pathways linked to T-cell receptors and Ras1.
  • PathDetect cis-reporter plasmid the pNFAT-Luc reporter plasmid (Stratagene, Inc. catalog #219094), containing the NFAT binding site from the human IL-2 gene.2,7-9.
  • the NFAT cis-reporting system includes the transfection-ready pNFAT-Luc reporter plasmid and the pCIS-CK negative control plasmid.
  • the backbone of the 5749-base-pair pNFAT-Luc plasmid is the pFR-Luc reporter plasmid of the aforementioned PathDetect trans-reporting system.
  • the GAL4 binding element was replaced with four direct repeats of the NFAT binding sequence (-286 to -257) from the IL-2 gene promoter, the most studied and widely used NFAT binding sequence.
  • activation of the luciferase gene indicated interaction of uncharacterized gene products, extracellular stimuli, growth factors, or drug candidates with specific enhancer elements. Then a plasmid expressing the gene of interest was cotransfected into mammalian cells along with a cis-reporter plasmid to indicate transcription activation.
  • NFAT proteins can be activated by the protein kinase C activator phorbol ester (PMA) in combination with the calcium ionophore ionomycin, reagents that raise free intracellular calcium.
  • PMA protein kinase C activator phorbol ester
  • luciferase activity increased by 13- and 16-fold, respectively. Therefore, the enhancer element in the pNFAT-Luc plasmid is responsive to calcium mobilization.
  • Cells transfected with pNFAT-Luc and then treated with either PMA or ionomycin alone did not show a significant increase in luciferase activity.
  • Cyclosporin inhibits the activity of calcineurin, a protein phosphatase regulated by intracellular calcium mobilization. All the isoforms of NFAT protein contain a calcineurin-binding domain and are activated by calcineurin. The inhibition of luciferase expression from pNFAT-Luc in the present model, in both Jurkat and CHO cells induced by PMA and ionomycin, was monitored for cyclosporin (as a positive control) and the cyclosporin analogs of the present invention.
  • rat basophilic leukemia cells stably transfected with chemokine receptors were transfected with pNFAT-Luc and then treated with their respective ligands (data not shown).
  • luciferase expression correlated very well with calcium mobilization. Therefore, luciferase expression from pNFAT-Luc indeed reflects the activation of endogenous NFAT proteins by calcium immobilization.
  • lymphocytes from the spleen of OFI female mice are co-cultured with ca. 3 ⁇ 7 sheep erythrocytes for 3 days. Test substance is added to the incubation medium in varying concentrations. Lymphocytes are harvested and plated onto agar with fresh sheep erythrocytes as antigen. Sensitized lymphocytes secrete antibody that coats the erythrocytes, which lyse to form a plaque in the presence of complement. Activity is assessed by reduction in the number of plaque forming, i.e., antibody product, cells.
  • mice having BALB/cByJ or any other acceptable strain
  • test compound (1 to 10%
  • vehicle or the positive control cyclophosphamide (Cyclosporin A)
  • mice are anesthetized and their abdomens shaved. 100 ⁇ l of a 3% solution of ovalbumin are applied to the abdomen and dried. Seven days later, the mice are challenged by applying 5 ⁇ l of ovalbumin to each side of the right ear. After 24 hours, both the right and left ear thickness are measured using a micrometer caliper.
  • an inducer phenytoin
  • mice footpad having BALB/cByJ or any other acceptable strain.
  • ester and control agent using graded doses, for example, 2.5, 10, 20 mg/Kg (based on cyclosporine A data).
  • graded doses for example, 2.5, 10, 20 mg/Kg (based on cyclosporine A data).
  • the popliteal lymph nodes are excised from the dosed mice and the lymph nodes are weighed.
  • single cell suspensions of each lymph node are prepared and enumerated.
  • the weight index for each animal is calculated (for example, a mean weight index ⁇ 2 would indicate suppression of immune response).
  • Challenge is effected employing a saline solution of OA, nebulized for discharge into an exposure chamber. Test animals are exposed to OA by nose-only inhalation for 60 minutes. For inhalation studies, OA solution is used at a concentration of 0.01%.
  • Test substance is administered (a) inhalation and/or (b) orally.
  • test substance is administered p.o. in olive oil 1 ⁇ daily for 3 days or in powder form in methylcellulose once prior to OA challenge. On day 3, test animals receive test substance 1.5 hrs. prior to and 6 hrs. after OA challenge.
  • test substance is micronised for delivery to test animals restrained within a flow-past, nose-only inhalation chamber. Administration by inhalation is effected 15 mins. prior to OA challenge.
  • Efficacy of administered test substance is determined by bronchoalveolar lavage (BAL) and cell counting.
  • animals are sacrificed with Na pento-barbitone (100 mg/kg i.p.) and the trachea is exposed and cannulated.
  • 5 successive 10 ml aliqots of Ca 2 + and Mg 2 + free Hank's balanced salt solution (HBSS), containing bovine serum albumin (BSA, 0.3%), EDTA (10 mM) and HEPES (10 mM) is then introduced into the lung and immediately aspirated by gentle compression of the lung tissue. Total cell counts in pooled eluates are determined using an automatic cell counter.
  • Lavage fluid is centrifuged at 200 g for 10 minutes and the cell pellet resuspended in 1 ml of supplemented HBSS. 10 ⁇ l of this cell suspension is added to 190 ⁇ l of Turk's solution (1:20) dilution). Differential cell counts are made from smears stained by Diff-Quick. Cells are identified and counted under oil immersion ( ⁇ 1,000). A minimum of 500 cells per smear are counted and the total population of each cell type is calculated.
  • OA challenge induces increase of all cell types in BAL fluid 24 hours after challenge.
  • Prior administration of cyclosporin analogs in accordance with the present invention by inhalation at dosages of the order of from 1.0 to 15.0 mg/kg reduces eosinophil count in BAL in a dose dependent manner as compared with untreated controls. Cell counts for other leucocytes (macrophages, neutrophils etc.) are also reduced.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US09/975,923 2001-10-12 2001-10-12 Cyclosporin analogs for the treatment of lung diseases Abandoned US20030087813A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/975,923 US20030087813A1 (en) 2001-10-12 2001-10-12 Cyclosporin analogs for the treatment of lung diseases
AU2002362774A AU2002362774A1 (en) 2001-10-12 2002-10-11 Cyclosporin analogs for the treatment of lung diseases
PCT/US2002/032646 WO2003030834A2 (fr) 2001-10-12 2002-10-11 Analogues de cyclosporine pour le traitement de maladies pulmonaires
US10/345,855 US20030109425A1 (en) 2001-10-12 2003-01-16 Cyclosporin analogs for the treatment of lung diseases
US10/349,877 US6979671B2 (en) 2001-10-12 2003-01-23 Cyclosporins for the treatment of immune disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/975,923 US20030087813A1 (en) 2001-10-12 2001-10-12 Cyclosporin analogs for the treatment of lung diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/345,855 Division US20030109425A1 (en) 2001-10-12 2003-01-16 Cyclosporin analogs for the treatment of lung diseases
US10/349,877 Continuation-In-Part US6979671B2 (en) 2001-10-12 2003-01-23 Cyclosporins for the treatment of immune disorders

Publications (1)

Publication Number Publication Date
US20030087813A1 true US20030087813A1 (en) 2003-05-08

Family

ID=25523566

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/975,923 Abandoned US20030087813A1 (en) 2001-10-12 2001-10-12 Cyclosporin analogs for the treatment of lung diseases
US10/345,855 Abandoned US20030109425A1 (en) 2001-10-12 2003-01-16 Cyclosporin analogs for the treatment of lung diseases
US10/349,877 Expired - Fee Related US6979671B2 (en) 2001-10-12 2003-01-23 Cyclosporins for the treatment of immune disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/345,855 Abandoned US20030109425A1 (en) 2001-10-12 2003-01-16 Cyclosporin analogs for the treatment of lung diseases
US10/349,877 Expired - Fee Related US6979671B2 (en) 2001-10-12 2003-01-23 Cyclosporins for the treatment of immune disorders

Country Status (3)

Country Link
US (3) US20030087813A1 (fr)
AU (1) AU2002362774A1 (fr)
WO (1) WO2003030834A2 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235716A1 (en) * 2003-03-17 2004-11-25 Molino Bruce F. Novel cyclosporins
US20060035821A1 (en) * 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US20060035822A1 (en) * 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US20060069016A1 (en) * 2004-09-29 2006-03-30 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US20060069015A1 (en) * 2004-09-29 2006-03-30 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US20060074015A1 (en) * 2004-10-06 2006-04-06 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US20060105945A1 (en) * 2004-11-15 2006-05-18 Allergan, Inc. Therapeutic methods using cyclosporine components
US20060105944A1 (en) * 2004-11-15 2006-05-18 Allergan, Inc. Methods for the therapeutic use of cyclosporine components
US20070232531A1 (en) * 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US20070299004A1 (en) * 2003-09-15 2007-12-27 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin compontnts
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20100209390A1 (en) * 2009-02-19 2010-08-19 Yat Sun Or Cyclosporin analogues
US20110008286A1 (en) * 2009-07-09 2011-01-13 Guoqiang Wang Novel proline substituted cyclosporin analogues
US20110008284A1 (en) * 2009-07-09 2011-01-13 Xuri Gao Novel clyclosporin analogues
US20110008285A1 (en) * 2009-07-09 2011-01-13 Jiang Long Novel cyclosporin analogues
US20110206637A1 (en) * 2010-02-23 2011-08-25 Yat Sun Or Antiviral agents
US8367618B2 (en) 2009-01-30 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US9200038B2 (en) 2010-12-15 2015-12-01 Ciclofilin Pharmaceuticals Corp. Cyclosporine analogue molecules modified at amino acid 1 and 3
US9221878B2 (en) 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9387230B2 (en) 2011-04-18 2016-07-12 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110666A1 (en) * 2002-12-04 2004-06-10 Or Yat Sun Cyclosporins for the treatment of immune disorders
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
US7557082B2 (en) 2006-03-03 2009-07-07 Allergan, Inc. Treatment with cyclosporin A
CA2694329A1 (fr) 2007-08-01 2009-02-05 Emory University Procedes de determination d'une activite de proteine phosphatase et son utilisation dans la prediction de resultats therapeutiques
CA2701482C (fr) 2007-10-08 2018-10-23 Lux Biosciences, Inc. Compositions ophtalmiques comprenant des inhibiteurs de la calcineurine ou des inhibiteurs de mtor
JP5726733B2 (ja) * 2008-07-30 2015-06-03 シクロフィリン ファーマシューティカルズ コープ． 非免疫抑制性シクロスポリン類似体分子
CA2763893A1 (fr) * 2009-06-02 2010-12-09 Nikan Pharmaceuticals, Llc Antagonisme du recepteur du peptide formyl humain dans le traitement de maladies
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE43335T1 (de) * 1980-02-14 1989-06-15 Sandoz Ag Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US5239057A (en) * 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US5427960A (en) * 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
DE3884470T2 (de) 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
EP0578616A3 (en) * 1992-07-09 1994-06-01 Sandoz Ltd Cylosporin synthetase
DE69832984T2 (de) * 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
CA2334730C (fr) 1998-06-12 2009-09-29 C-Chem Ag Nouvelles cyclosporines
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US6784156B2 (en) * 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
US20040110666A1 (en) * 2002-12-04 2004-06-10 Or Yat Sun Cyclosporins for the treatment of immune disorders
US7012065B2 (en) * 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235716A1 (en) * 2003-03-17 2004-11-25 Molino Bruce F. Novel cyclosporins
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
US20070299004A1 (en) * 2003-09-15 2007-12-27 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin compontnts
US8629111B2 (en) 2003-09-15 2014-01-14 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8618064B2 (en) 2003-09-15 2013-12-31 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8633162B2 (en) 2003-09-15 2014-01-21 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US9248191B2 (en) 2003-09-15 2016-02-02 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8685930B2 (en) 2003-09-15 2014-04-01 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8648048B2 (en) 2003-09-15 2014-02-11 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US8642556B2 (en) 2003-09-15 2014-02-04 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20060035822A1 (en) * 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US7226906B2 (en) 2004-08-16 2007-06-05 Array Biopharma, Inc. Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US20060035821A1 (en) * 2004-08-16 2006-02-16 Hunt Kevin W Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US20060069016A1 (en) * 2004-09-29 2006-03-30 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US20060069015A1 (en) * 2004-09-29 2006-03-30 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20060074015A1 (en) * 2004-10-06 2006-04-06 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US7632807B2 (en) 2004-10-06 2009-12-15 Albany Molecular Research, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US20080153744A1 (en) * 2004-10-06 2008-06-26 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7151085B2 (en) 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US20060247158A1 (en) * 2004-11-15 2006-11-02 Allergan, Inc. Therapeutic methods using cyclosporine components
US7368426B2 (en) 2004-11-15 2008-05-06 Allergan, Inc. Methods for the therapeutic use of cyclosporine components
US7135455B2 (en) 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US9457060B2 (en) 2004-11-15 2016-10-04 Allergan, Inc. Therapeutic methods using cyclosporine components
US20060105944A1 (en) * 2004-11-15 2006-05-18 Allergan, Inc. Methods for the therapeutic use of cyclosporine components
US20060199760A1 (en) * 2004-11-15 2006-09-07 Allergan, Inc. Methods for the therapeutic use of cyclosporine components
US20060105945A1 (en) * 2004-11-15 2006-05-18 Allergan, Inc. Therapeutic methods using cyclosporine components
US7902155B2 (en) 2004-11-15 2011-03-08 Allergan, Inc. Therapeutic methods using cyclosporine components
US10736936B2 (en) 2004-11-15 2020-08-11 Allergan, Inc. Therapeutic methods using cyclosporine components
US20060247159A1 (en) * 2004-11-15 2006-11-02 Allergan, Inc. Therapeutic methods using cyclosporine components
US20070232531A1 (en) * 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US8367618B2 (en) 2009-01-30 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20100209390A1 (en) * 2009-02-19 2010-08-19 Yat Sun Or Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US20110008285A1 (en) * 2009-07-09 2011-01-13 Jiang Long Novel cyclosporin analogues
US20110008284A1 (en) * 2009-07-09 2011-01-13 Xuri Gao Novel clyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110008286A1 (en) * 2009-07-09 2011-01-13 Guoqiang Wang Novel proline substituted cyclosporin analogues
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US20110206637A1 (en) * 2010-02-23 2011-08-25 Yat Sun Or Antiviral agents
US9200038B2 (en) 2010-12-15 2015-12-01 Ciclofilin Pharmaceuticals Corp. Cyclosporine analogue molecules modified at amino acid 1 and 3
US9714271B2 (en) 2010-12-15 2017-07-25 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
US9387230B2 (en) 2011-04-18 2016-07-12 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US9221878B2 (en) 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection

Also Published As

Publication number Publication date
AU2002362774A1 (en) 2003-04-22
WO2003030834A3 (fr) 2004-04-15
US20030166515A1 (en) 2003-09-04
US6979671B2 (en) 2005-12-27
US20030109425A1 (en) 2003-06-12
WO2003030834A2 (fr) 2003-04-17

Similar Documents

Publication Publication Date Title
US20030087813A1 (en) Cyclosporin analogs for the treatment of lung diseases
US6784156B2 (en) Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en) Cyclosporin analogs for the treatment of autoimmune diseases
US5643870A (en) O-acylated cyclosporins
US7468419B2 (en) Cyclosporin derivatives for the treatment of immune disorders
JP2002519434A (ja) 活性の特徴が改善された新規のシクロスポリン
EP0373260B1 (fr) Dérivés de cyclosporine avec un acide aminé modifié en position 8
CA2021788C (fr) Derives de cyclosporine
US20040110666A1 (en) Cyclosporins for the treatment of immune disorders
HK1004268B (en) Cyclosporin derivatives
EP0470995A1 (fr) Utilisation de composes steroidiques sous forme d'agents antifongiques.
EP0687686A1 (fr) Aureobasidines
AU2002245567A1 (en) Cyclosporins for the treatment of respiratory diseases
JP4493891B2 (ja) エキノカンジンの新誘導体、それらの製造方法及びそれらの抗菌剤としての使用
JPH0717677B2 (ja) “８−アミノ酸”に改良のある新規シクロスポリン誘導体

Legal Events

Date Code Title Description
AS Assignment

Owner name: ENANTA PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OR, YAT SUN;LAZAROVA, TSVETELINA IVANOVA;REEL/FRAME:012255/0383;SIGNING DATES FROM 20010927 TO 20010928

AS Assignment

Owner name: SILICON VALLEY BANK DBA SILICON VALLEY EAST, CALIF

Free format text: SECURITY AGREEMENT;ASSIGNOR:ENANTA PHARMACEUTICALS, INC.;REEL/FRAME:013957/0709

Effective date: 20030710

AS Assignment

Owner name: ENANTA PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: SECURITY AGREEMENT;ASSIGNOR:SILICON VALLEY BANK DBA SILICON VALLEY EAST;REEL/FRAME:014269/0426

Effective date: 20040105

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION